Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR).
Growth Horm IGF Res
; 36: 11-15, 2017 10.
Article
en En
| MEDLINE
| ID: mdl-28822957
ABSTRACT
CONTEXT Twenty-five to 40% of patients with well-controlled X-linked hypophosphatemic rickets (XLHR) have a final height under -2 SDS. Previous studies have shown that recombinant human growth hormone (rhGH) treatment improves linear growth in short children with XLHR. OBJECTIVE:
We studied the effectiveness of rhGH treatment in children with XLHR in a larger cohort.DESIGN:
Monocentric, prospective, non-randomized trial.SETTING:
University hospital in France. PATIENTS 19 patients with XLHR and a mutation in the PHEX gene. Six male and 6 female Tanner stage 1 patients (age 6.1±2.4years) and 4 male and 3 female Tanner stage 2 patients (age 13.1±1years). At inclusion, height SDS was -2.35±0.8 SDS and growth velocity was -1.12±1.2 SDS. INTERVENTION 2years of treatment with 67mcg/kg/day of rhGH at initiation. Every three months rhGH dosage was adjusted using an IGF-1 dosing protocol. MAIN OUTCOMEMEASURES:
Comparison in change from baseline to year 2 in height and growth velocity.RESULTS:
Height SDS improved from -2.35±0.8 SDS at baseline, to -1.62±0.8 SDS (p=0.01) after one and to -1.2±1 SDS (p=0.04) after two years of rhGH treatment. There was a strong correlation (r2=0.6104, p<0.0001) between the age of onset of rhGH treatment and the number of cm gained over the study period. Pre-pubertal patients height SDS improved compared to baseline height SDS after one (-1.5±0.7, p<0.03) and two (-0.96±1, p<0.03) years of rhGH treatment. In pubertal patients there was no significant improvement in height SDS after one year (-1.75±1) and after two years (-1.7±0.8) of rhGH treatment.CONCLUSION:
Two-year rhGH treatment is effective to treat short stature in XLHR children. Pre-pubertal children responded better to rhGH. CLINICAL TRIAL REGISTRATION NUMBER NCT02720770.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Estatura
/
Pubertad
/
Hormona de Crecimiento Humana
/
Enfermedades Genéticas Ligadas al Cromosoma X
/
Raquitismo Hipofosfatémico Familiar
Tipo de estudio:
Clinical_trials
/
Guideline
/
Observational_studies
Idioma:
En
Revista:
Growth Horm IGF Res
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2017
Tipo del documento:
Article